PMID- 7672797
OWN - NLM
STAT- MEDLINE
DCOM- 19951018
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 26
IP  - 9
DP  - 1995 Sep
TI  - Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the 
      urinary bladder.
PG  - 970-8
AB  - Frequent recurrences and multicentricity of bladder cancer suggest that 
      alterations of the urothelium distant from the tumor may be relevant to 
      prognosis. In this study immunohistochemistry and fluorescence in situ 
      hybridization (FISH) were used to examine expression of p53, erbB-2, and 
      epidermal growth factor receptor (EGF-r), genomic aberrations, and tumor cell 
      proliferation (Ki67 LI) in normal and dysplastic urothelium. Biopsy specimens 
      examined included normal urothelium (n = 40), mild dysplasia (n = 34), moderate 
      dysplasia (n = 18) and carcinoma in situ (CIS; n = 20). Several different 
      oncogene expression patterns were found, only some of which were associated with 
      dysplasia. EGF-r expression was equally frequent in normal and dysplastic 
      urothelium and showed a strong association with Ki67 LI (P < .0001). A purely 
      superficial erbB-2 positivity was present in both normal and dysplastic biopsies. 
      However, diffuse erbB-2 positivity and p53 overexpression were both associated 
      with advanced dysplasia (P < .0001 each). FISH analysis showed erbB-2 gene 
      amplification and p53 deletions in selected CIS, as well as a marked chromosome 
      17 copy number heterogeneity in all six CIS examined. These findings indicate a 
      considerable genomic instability in bladder CIS. They show that both erbB-2 and 
      p53 are altered during malignant transformation. Detectable oncogene expression 
      alone, however, is not diagnostic of malignancy in bladder urothelium.
FAU - Wagner, U
AU  - Wagner U
AD  - Institute of Pathology, University of Basel, Switzerland.
FAU - Sauter, G
AU  - Sauter G
FAU - Moch, H
AU  - Moch H
FAU - Novotna, H
AU  - Novotna H
FAU - Epper, R
AU  - Epper R
FAU - Mihatsch, M J
AU  - Mihatsch MJ
FAU - Waldman, F M
AU  - Waldman FM
LA  - eng
GR  - CA47537/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - Humans
MH  - Immunohistochemistry
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Precancerous Conditions/*metabolism/pathology
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Tumor Suppressor Protein p53/genetics/*metabolism
MH  - Urinary Bladder Neoplasms/*metabolism/pathology
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 0046-8177(95)90086-1 [pii]
AID - 10.1016/0046-8177(95)90086-1 [doi]
PST - ppublish
SO  - Hum Pathol. 1995 Sep;26(9):970-8. doi: 10.1016/0046-8177(95)90086-1.